Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran

First Posted Date: 2017-08-23

Last Posted Date: 2020-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1489

Registration Number: NCT03258645

Locations: 🇸🇪
SITS International (c/o Karolinska University Hospital), Stockholm, Sweden

This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 685509

First Posted Date: 2017-08-23

Last Posted Date: 2018-07-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT03259464

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin/linagliptin/metformin HCl
Drug: Empagliflozin
Drug: Linagliptin
Drug: Metformin HCl

First Posted Date: 2017-08-23

Last Posted Date: 2020-03-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT03259490

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Warfarin
Drug: Dabigatran

First Posted Date: 2017-08-18

Last Posted Date: 2019-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22490

Registration Number: NCT03254134

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Medical Need of OAC Reversal

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: warfarin
Drug: dabigatran
Drug: Apixaban
Drug: Edoxaban
Drug: Rivaroxaban

First Posted Date: 2017-08-18

Last Posted Date: 2019-03-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53969

Registration Number: NCT03254147

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan

Completed

Conditions: Pulmonary Fibrosis

Interventions: Drug: nintedanib
Drug: pirfenidone

First Posted Date: 2017-08-08

Last Posted Date: 2021-04-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 101

Registration Number: NCT03242759

Locations: 🇨🇳
Chang-Hua Christian Hospital, Changhua, Taiwan
🇨🇳
Chang Gung Memorial Hospital(Linkou), Tao-Yuan, Taiwan
🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

and more 7 locations

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone propionate
Drug: Tiotropium
Drug: Salmeterol
Drug: Olodaterol

First Posted Date: 2017-08-07

Last Posted Date: 2020-04-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 302

Registration Number: NCT03240575

Locations: 🇺🇸
Pulmonary Rsrch Inst of SE MI, Farmington Hills, Michigan, United States
🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 39 locations

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

Phase 2

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: BI 1467335
Drug: Placebo

First Posted Date: 2017-08-03

Last Posted Date: 2021-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 79

Registration Number: NCT03238963

Locations: 🇺🇸
Trinity Research, Dothan, Alabama, United States
🇮🇹
Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy
🇮🇹
IRCCS Fondazione Bietti, Roma, Italy

and more 32 locations

This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550
Drug: Placebo

First Posted Date: 2017-07-26

Last Posted Date: 2018-04-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT03230487

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Phase 2

Terminated

Conditions: Psychotic Disorders

Interventions: Drug: BI 409306
Drug: Placebo

First Posted Date: 2017-07-26

Last Posted Date: 2022-06-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT03230097

Locations: 🇺🇸
Michigan Clinical Research Institute PC, Ann Arbor, Michigan, United States
🇺🇸
Precise Research Centers, Flowood, Mississippi, United States
🇺🇸
PRIME Clinic, New Haven, Connecticut, United States

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy